Staying up to date on screening may cut risk of death from CRC

Staying up to date on screening was associated with a 62% decrease in the odds of dying from colorectal cancer.

Expert Q&A: What’s new in alopecia areata research and treatment?

LAS VEGAS – Dr. Maria Hordinsky addresses treatment issues and more, in an interview at the Las Vegas Dermatology Seminar.

Invasive strategy increased bleeding risk in frail older AMI patients

Registry analysis suggests frailty in an AMI patient calls for personalized decision making.

HCV antibodies linked to poorer cardiac outcomes in ACHD patients

Adults with congenital heart disease and HCV antibody positivity had significantly worse cardiac outcomes.

Quality of life with PAD follows function, not clinical markers

Patients with symptomatic PAD rate their health-related quality of life based on functional capabilities, not markers of disease severity or comorbidities.

Higher prenatal exposure to daylight tied to lower depression risk

Exposure and birth in northern latitudes conferred a 7% risk for lifetime depression, compared with southern latitudes, where risk increased to 15%.

Questions, documentation, and lab tests are crucial in alopecia areata

LAS VEGAS – Alopecia areata affects an estimated 1.7%-2.1% of the population and is sporadic in 50%-80% of cases.

Stubborn derm condition? Don’t just rely on emails and data

MONTEREY, CALIF. – Specialty pharmacies, medical alliances, and anecdotal evidence are all helpful.

Beware drug reactions from methotrexate, voriconazole, and BRAF inhibitors

MONTEREY, CALIF. – Two drugs – and a drug class commonly used in oncologic dermatology – can produce a variety of skin-related adverse events.

Sunscreens: Misleading labels, poor performance, and hype about their risks

MONTEREY, CALIF. – While they’re getting better, sunscreen quality varies and consumers face mixed messages, an expert says that.

Pages